<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484884</url>
  </required_header>
  <id_info>
    <org_study_id>17-538</org_study_id>
    <nct_id>NCT03484884</nct_id>
  </id_info>
  <brief_title>A Study of Optical Imaging With Light From Radiotracers in Cancer Patients</brief_title>
  <official_title>A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test Cerenkov luminescence imaging, which is a different way&#xD;
      to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal&#xD;
      metastases in the neck, supraclavicular, axillary and/or inguinal region.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%</measure>
    <time_frame>Through study completion, an average of 24 hours</time_frame>
    <description>The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Thyroid cancer/nodal metastasis</arm_group_label>
    <description>Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerenkov luminescence imaging.</intervention_name>
    <description>Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.</description>
    <arm_group_label>Thyroid cancer/nodal metastasis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants will be identified by a member of the patient's treatment team, the&#xD;
        protocol investigator, or research team.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is 18 years of age or old&#xD;
&#xD;
          -  Participant must meet one of the following:&#xD;
&#xD;
               -  Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I&#xD;
&#xD;
               -  Patients with any tumors with (existing or suspected) nodal metastases in the&#xD;
                  neck, supraclavicular, axillary and/or inguinal region who are scheduled to&#xD;
                  receive a clinical FDG PET/CT scan&#xD;
&#xD;
               -  Patients with metastatic prostate cancer who are schedule for Xofigo therapy with&#xD;
                  223Ra&#xD;
&#xD;
               -  Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi&#xD;
                  PET scan in the Nuclear Medicine Clinic&#xD;
&#xD;
               -  Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients imaged for Cerenkov luminescence are going to be required to be in a darkened&#xD;
             enclosure for at least 10 minutes and sit still during image acquisition. Any&#xD;
             conditions that would prevent this will exclude the patients. This includes patients&#xD;
             who unable to sit in a dark environment, have claustrophobic, inability to sit still&#xD;
             for a few minutes&#xD;
&#xD;
          -  Any other past medical, physiological or demographic concerns. This includes any&#xD;
             patients with skin blemishes that are present at the dermis over the tumor, as these&#xD;
             are of particular interest for use of this technique. This also includes open wounds&#xD;
             on the area of interest.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Grimm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Grimm, MD, PhD</last_name>
    <phone>1646-888-3095</phone>
    <email>grimmj@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Snehal Patel, MD, FRCS</last_name>
    <phone>1212-639-3412</phone>
    <email>patels@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Grimm, MD, PhD</last_name>
      <phone>646-888-3095</phone>
      <email>grimmj@mskcc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nodal metastases</keyword>
  <keyword>17-538</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

